生物来源
human
质量水平
形式
lyophilized powder
来源
USA origin
技术
cell culture | mammalian: suitable
杂质
virus, tested
运输
dry ice
储存温度
−20°C
相关类别
一般描述
补体血清从混合的人血浆中制备，并根据标签上指示的血清量进行冻干。
应用
人补体血清已用于：
- 培养DLD-1或SW-620细胞，以量化C5a释放
- 多重头抗体C3d结合试验
- 补体依赖性细胞毒性试验
人补体血清已用于：
- 培养DLD-1或SW-620细胞，以量化C5a释放
- 多重头抗体C3d结合试验
- 补体依赖性细胞毒性试验
补体血清的活性可通过体外溶血试验测定。
外形
由标签所示含量血清制成的冻干粉末
分析说明
溶血滴度（CH50单位/ml）通过Kabat/Mayer法测定。实际滴度见标签。
免责声明
仅供研究使用。本品在法国的科研应用受到监管，包括用于进口和出口活动（法国《公共卫生法典》Public Health Code Article L 1211-1 paragraph 2）。如《公共卫生法典》所述，购买者（即最终用户）需要从法国研究部(France Ministry of Research)获得进口授权。订购此产品即代表您已确认获得合法的进口授权。
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
高风险级别生物产品--人源产品
David A Spencer et al.
Nature communications, 13(1), 662-662 (2022-02-05)
Increasingly, antibodies are being used to treat and prevent viral infections. In the context of HIV, efficacy is primarily attributed to dose-dependent neutralization potency and to a lesser extent Fc-mediated effector functions. It remains unclear whether augmenting effector functions of
Anaïs Thiriard et al.
Frontiers in immunology, 14, 1107156-1107156 (2023-04-04)
To comprehensively analyze the quality of the antibody response between children with Multisystem inflammatory syndrome (MIS-C) and age-matched controls at one month after SARS-CoV-2 exposure, and infected in the same time-period. Serum from 20 MIS-C children at admission, and 14
Yui Suzuki et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(14), 4388-4399 (2019-04-26)
The anti-CCR4 mAb, mogamulizumab, offers therapeutic benefit to patients with adult T-cell leukemia-lymphoma (ATL), but skin-related adverse events (AE) such as erythema multiforme occur frequently. The purpose of this study was to determine the mechanisms by which mogamulizumab causes skin-related
Helen Kotanides et al.
Cancer immunology research, 8(10), 1300-1310 (2020-09-03)
The programmed cell death protein 1 receptor (PD-1) and programmed death ligand 1 (PD-L1) coinhibitory pathway suppresses T-cell-mediated immunity. We hypothesized that cotargeting of PD-1 and PD-L1 with a bispecific antibody molecule could provide an alternative therapeutic approach, with enhanced
Lisa Tomasi et al.
Open forum infectious diseases, 9(11), ofac554-ofac554 (2022-12-06)
The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门